DCAL vs MANGALAM: Stock Comparison

Dishman Carbogen Amcis Limited vs Mangalam Drugs And Organics Limited

Live data: 22 July 2026, 2:53 PM IST • Source: NSE and company filings

Dishman Carbogen Amcis Limited is the larger company by market capitalisation. Dishman Carbogen Amcis Limited shows a higher ROE, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Dishman Carbogen Amcis Limited and Mangalam Drugs And Organics Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, DCAL is more favourable on 9 of 11 scored metrics and MANGALAM on 1These counts are context-free and are not an overall rating.

Key Differences

Market Cap
DCAL is the larger company
₹2,916 Cr vs ₹43 Cr
EPS
DCAL has higher earnings per share
₹6.22 vs ₹-28.05
Revenue Growth (TTM YoY)
DCAL has faster revenue growth
18.9% vs -7.5%
EPS Growth (TTM YoY)
MANGALAM has faster EPS growth
0% vs -49.5%
Qtr Sales Growth
DCAL has stronger quarterly sales growth
18.8% vs -7.54%
Qtr Profit Growth
DCAL has stronger quarterly profit growth
-59.4% vs -22,467%
ROE
DCAL has a higher ROE
1.58% vs -35.2%
ROCE
DCAL has a higher ROCE
3.15% vs -14.3%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricDCALMANGALAM
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricDCALMANGALAM
Live Price₹187.03₹27.08
Day Change-1.66%-0.66%
Volume1.52 L25,356
52-Week High₹321.95₹95
52-Week Low₹128.5₹22.8
Distance from 52W High-41.91%-71.49%

Valuation

MetricDCALMANGALAM
Market Cap₹2,916 Cr₹43 Cr
P/E Ratio30.58x
P/B Ratio0.45x
EPS₹6.22₹-28.05
Book Value₹426.9₹65.12
Dividend Yield0%0%

Growth

MetricDCALMANGALAM
Revenue Growth (TTM YoY)18.9%-7.5%
EPS Growth (TTM YoY)-49.5%0%
Qtr Sales Growth18.8%-7.54%
Qtr Profit Growth-59.4%-22,467%

Profitability & Leverage

MetricDCALMANGALAM
ROE1.58%-35.2%
ROCE3.15%-14.3%
Net Margin2.51%-19.13%
Operating Margin19.3%-6.42%
Debt to Equity0.46x1.02x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricDCALMANGALAM
Promoter Holding59.32%35.65%
FII Holding7.45% 0.21 pp0.11% 0.21 pp
DII Holding1.63% 0.36 pp0%
Public Holding31.6% 0.15 pp64.24% 0.22 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Dishman Carbogen Amcis Limited and Mangalam Drugs And Organics Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.